格列吡嗪控释片联合甘精胰岛素治疗2型糖尿病的Meta分析

目的：利用Meta分析方法对格列吡嗪控释片联合甘精胰岛素治疗2型糖尿病的临床试验进行分析,主要比较格列吡嗪控释片联合甘精胰岛素与中效低糖蛋白锌人胰岛素（NPH）治疗糖尿病的有效性和不良反应的差异,评价其治疗效果。方法：检索2000-2007年国内发表的格列吡嗪控释片联合甘精胰岛素治疗2型糖尿病临床试验的相关文献,采用软件对符合条件的文献进行分析。结果：（1）同质性检验：有效性,χ^2=11.35,自由度5;不良反应差异,χ^2=22.54,自由度5,两者P均〉0.05。（2）合并效应量的估计：有效性,OR合并=-0.17,OR合并95%的可信区间-0.20 - -0.13。不良反应差异,OR合并=0.52,OR合并95%的可信区间-0.20 - -0.13。结论：甘精胰岛素、中效低糖蛋白锌人胰岛素降血糖疗效相似,甘精胰岛素低血糖发生率低于中效低糖蛋白锌人胰岛素。

Meta-analysis of Glargine Combined with Glipizide Extended - release Tablets in the Treatment of Type Ⅱ Diabetes Patients

OBJECTIVE： To conduct a meta - analysis on the clinic trials of the Glargine combined with glipizide extended - release tablets in the treatment of type 2 diabetes patients with an emphasis to compare the efficacy and the adverse effects between the Glargine combined with glipizide extended- release tablets and Human NPH and to evaluate the therapeutic outcome. METHODS： The pertinent domestic literature about the Glargine combined with glipizide extended - release tablets in the treatment of type 2 diabetes mellitus from 2000 to 2007 were reviewed, and the data were analyzed using the software. RESULTS： The homogeneity test showed that the cited studies of the efficacy and safety were homogeneous with Χ^2 = 11.35, Χ^2 = 22.54, P 〉 0.05; In the combined tests, the validity value of OR merging was equal to minus 0.17, the confidence interval was - 0.20 to - 0.13 of OR merging 95% ; In the difference of adverse effects test, the value of OR merging was equal to 0.52, the confidence interval was - 0.20 to - 0.13 of OR merging 95%. CONCLUSION： There is no significant difference in the efficacy for diabetes between the insulin Glargine and Human NPH, but the incidence of hypoglycaemia in insulin glargine - treated group is lower than in NPH - treated group.